A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425

Blood

Volumn 114, Issue 10, 2009, Pages 2051-2059

  Schwartz, Cindy L ^a   Constine, Louis S ^b   Villaluna, Doojduen ^c   London, Wendy B ^d   Hutchison, Robert E ^e   Sposto, Richard ^f   Lipshultz, Steven E ^g   Turner, Charles S ^h   DeAlarcon, Pedro A ⁱ   Chauvenet, Allen ^j  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁱ St Jude Midwest Affiliate   (United States)

^j WEST VIRGINIA UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; PREDNISONE; PROCARBAZINE; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL TRIAL; CYTOPENIA; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; HEART DISEASE; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; ILEUS; INFECTION; LONG TERM CARE; LUNG DISEASE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; RISK ASSESSMENT; RISK REDUCTION; SCHOOL CHILD; SECONDARY MALIGNANCY; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TYPHLITIS; WEAKNESS; DISEASE FREE SURVIVAL; MORTALITY; MULTICENTER STUDY; PRESCHOOL CHILD; SURVIVAL RATE; TIME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; PREDNISOLONE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TIME FACTORS;

EID: 70349260655     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-184143     Document Type: Article

References (40)

1. DeVita VT Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980;92(5):587-595.
2. Santoro A, Bonadonna G, Bonfante V, et al. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med. 1982;306(13):770-775.
3. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol. 1986;4(9):1295-1306. (Pubitemid 16028022)
4. Van Rijswijk RE, Haanen C, Dekker AW, et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol. 1989;7(12):1776-1782. (Pubitemid 20014323)
5. Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol. 1983;1(2):146-153. (Pubitemid 14176804)
6. Livingston R. Single agents in Cancer Chemotherapy. New York, NY: IFI/Plenum; 1970;293-306.
7. Tebbi CK, Mendenhall N, London WB, Williams JL, de Alarcon PA, Chauvenet AR. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer. 2006;46(6):198-202. (Pubitemid 43076071)
8. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997;15(8):2769-2779.
9. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998;16(2):3810-3821. (Pubitemid 29001534)
10. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630-637. (Pubitemid 34111368)
11. National Cancer Institute. Common Toxicity Criteria. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcv20-4-30-992.pdf. Accessed May 13, 2009.
12. Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
13. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Statist Soc Ser A. 1972;135(2):185-198.
14. Savage I. Contributions to the theory of rank order statistics: the two sample case. Am Math Stat. 1956;27(3):590-615.
15. Brämswig JH, Heimes U, Heiermann E, et al. The effects of different cumulative doses of chemotherapy on testicular function: results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer. 1990;65(6):1298-1302. (Pubitemid 20097151)
16. De Bruin ML, Huisbrink J, Hauptmann M, et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood. 2008;111(1):101-108.
17. Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403-1409. (Pubitemid 8108291)
18. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
19. Bu'Lock FA, Mott MG, Oakhill A, et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms and pathophysiology. Br Heart J. 1995;73(4):340-350.
20. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20(18):3765-3771. (Pubitemid 35050830)
21. Hudson MM, Krasin M, Link MP. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol. 2004;22(22):4541-4550. (Pubitemid 41185121)
22. Dorffel W, Luders H, Ruhl U, et al. Preliminary results of the multicenter trial GPOH-HL 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr. 2003;215:139-145. (Pubitemid 36718285)
23. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23(36):9198-9207. (Pubitemid 46260175)
24. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med. 2003;348(24):2396-2406. (Pubitemid 36682818)
25. Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol. 2002;13[suppl 1]:107-111. (Pubitemid 34567413)
26. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991-4008. (Pubitemid 47477279)
27. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy: results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18(7):1500-1507. (Pubitemid 30205396)
28. Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol. 2002;13[suppl 1]:86-91. (Pubitemid 34567408)
29. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
30. Bhatia S, Robison LL, Oberlin O. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334(12):745-751. (Pubitemid 26089355)
31. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487-497. (Pubitemid 30078530)
32. Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008;72(1):24-33.
33. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst. 2003;95(13):971-980. (Pubitemid 36896714)
34. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85(9):3227-3232. (Pubitemid 30944530)
35. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325(9):599-605.
36. Constine LS, Donaldson SS, McDougall IR. Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer. 1984;53(4):878-883. (Pubitemid 14183747)
37. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270(16):1949- 1955. (Pubitemid 23312611)
38. Larson DL, Kroll S, Jaffe N, Serure A, Goepfert H. Long-term effects of radiotherapy in childhood and adolescence. Am J Surg. 1990;160(4):348-351.
39. Schwartz CL. The management of Hodgkin lymphoma in the young child. Curr Opin Pediatr. 2003;15(1):10-16.
40. Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer. 2007;110(11):2576-2586.